Press & news

Press releases

Matt Franklin, MBA, appointed as Biofidelity Non-Executive Director

Matt Franklin, MBA, appointed as Biofidelity Non-Executive Director

Nov 17. 2022
Biofidelity has expanded its Board of Directors to include Matt Franklin, MBA, who will join as a Non-Executive Director.
Biofidelity announces presentation of new data on novel genomic technology at AMP 2022

Biofidelity announces presentation of new data on novel genomic technology at AMP 2022

Oct 28. 2022
ASPYRE simplifies & accelerates the detection of biomarkers in both DNA & RNA to facilitate selection of the most effective targeted cancer treatments
New data demonstrates novel genomic technology provides ultra-sensitive detection of gene fusions from RNA

New data demonstrates novel genomic technology provides ultra-sensitive detection of gene fusions from RNA

Oct 18. 2022
Current sequencing methods miss gene fusions for many non-small cell lung cancer patients denying them access to targeted therapies.
Biofidelity granted key patents in US, Europe, and China

Biofidelity granted key patents in US, Europe, and China

Oct 11. 2022
New patents in global markets strengthen and secure intellectual property for innovative platform technology designed to remove the noise from genomic data
Biofidelity Raises $23M in Series A+ Financing led by  Octopus Ventures to Launch ASPYRE Technology | Biofidelity

Biofidelity Raises $23M in Series A+ Financing led by Octopus Ventures to Launch ASPYRE Technology | Biofidelity

Feb 1. 2022
Funding will enable expansion of US presence and acceleration of the commercialization of ASPYRE Cambridge, UK, February 1, 2022 — Biofidelity, a pioneer in …
Biofidelity Adds Lee N. Newcomer, MD to Scientific Advisory Board Ahead of ASPYRE Launch | Biofidelity

Biofidelity Adds Lee N. Newcomer, MD to Scientific Advisory Board Ahead of ASPYRE Launch | Biofidelity

Jan 6. 2022
Fast, multi-gene biomarker test designed to make targeted precision cancer treatments available to more patients Cambridge, UK, January 6, 2022 — …
New California Law Increases Access to Biomarker Testing for Late-Stage Cancer Patients | Biofidelity

New California Law Increases Access to Biomarker Testing for Late-Stage Cancer Patients | Biofidelity

Oct 13. 2021
SB 535 aims to reduce delays for the genetic testing that’s essential for selecting targeted, more effective cancer treatments Cambridge, UK, October 13, …
Successful alpha testing of Biofidelity’s ASPYRE-Lung reagents demonstrates  breakthrough capabilities and ease of use | Biofidelity

Successful alpha testing of Biofidelity’s ASPYRE-Lung reagents demonstrates breakthrough capabilities and ease of use | Biofidelity

Sep 14. 2021
ASPYRE-Lung panel set up and multiple samples analyzed in US & UK test labs in as little as one day Consistent performance demonstrated across test sites …
Biofidelity opens US headquarters and new cancer diagnostic laboratory | Biofidelity

Biofidelity opens US headquarters and new cancer diagnostic laboratory | Biofidelity

Jul 28. 2021
Facility in RTP North Carolina will enable US launch of precision diagnostics using breakthrough ASPYRE technology Cambridge, UK, 28 July 2021 – Biofidelity …
Biofidelity Announces Formation of Scientific Advisory Board | Biofidelity

Biofidelity Announces Formation of Scientific Advisory Board | Biofidelity

Jul 15. 2021
New Scientific Advisory Board combines decades of industry, academic and patient advocacy oncology leadership to help guide development & …